Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and 908 Devices (NASDAQ:MASS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Volatility and Risk
Anteris Technologies Global has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Valuation and Earnings
This table compares Anteris Technologies Global and 908 Devices”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anteris Technologies Global | $1.91 million | 498.42 | -$94.14 million | ($2.23) | -4.39 |
| 908 Devices | $56.20 million | 5.95 | $19.49 million | ($1.00) | -8.84 |
908 Devices has higher revenue and earnings than Anteris Technologies Global. 908 Devices is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Anteris Technologies Global and 908 Devices, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anteris Technologies Global | 1 | 0 | 4 | 0 | 2.60 |
| 908 Devices | 1 | 0 | 1 | 0 | 2.00 |
Anteris Technologies Global presently has a consensus target price of $16.00, suggesting a potential upside of 63.60%. 908 Devices has a consensus target price of $12.00, suggesting a potential upside of 35.75%. Given Anteris Technologies Global’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Anteris Technologies Global is more favorable than 908 Devices.
Insider and Institutional Ownership
88.1% of 908 Devices shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by company insiders. Comparatively, 28.2% of 908 Devices shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Anteris Technologies Global and 908 Devices’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anteris Technologies Global | -5,148.78% | -124.76% | -101.21% |
| 908 Devices | -62.40% | -14.03% | -10.40% |
Summary
908 Devices beats Anteris Technologies Global on 8 of the 14 factors compared between the two stocks.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
About 908 Devices
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
